Results 211 to 220 of about 33,041 (261)

Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy. [PDF]

Immunity
Cheng BY, Centeio RM, Chiu DK, Kiyohara CL, Herzog E, Dahan R, Thomas WE, Wang TT.   +7 more
europepmc   +1 more source

Receptor-mediated apoptosis in B cells From the regulation of B Cell survival to potential novel approaches for lymphoma therapy [PDF]

Eeva, Jonna
core  

Expansion of circulating T cells expressing low levels of the B cell-specific antigen CD20 (CD3 (+) CD20 (dim)) in patients with multiple myeloma.

, 2000
Katopodis, O, Sfikakis, PP, Viglis, V, Liossis, SNC, Pouli, A, Dimopoulos, MA   +5 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

CD20: A target antigen for immunotherapy of autoimmune diseases

Autoimmunity Reviews, 2005
This article reviews the role of CD20 antigen in B cell function and the effectiveness and limits of passive immunotherapy with anti-CD20 monoclonal antibody (Rituximab) in the treatment of autoimmune (or immune-mediated) diseases. Active immunotherapy is a more feasible way to control these chronic diseases.
Federico Perosa, Elvira Favoino, Marcella Prete   +2 more
exaly   +4 more sources

Ofatumumab and Granzyme B as immunotoxin against CD20 antigen

In Silico Pharmacology, 2022
Anti-CD20 antibodies such as ofatumumab has demonstrated efficacy in relapsed/refractory chronic lymphocytic leukemia, are among the most successful therapies to date. In this study, we have designed an immunotoxin composed of Granzyme B and the high affinity variant of Ofatumumab.
Fateme Sefid, Armina Alagheband Bahrami, Zahra Payandeh, Saeed Khalili, Ghasem Azamirad, Seyed Mehdy Kalantar, Maryam Touhidinia   +6 more
openaire   +2 more sources

Development of a Mimotope-Based Vaccine Against CD20 Antigen

Protein & Peptide Letters, 2007
CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to ...
Meng, Li, Wei, Han, Quiyang, Zhang, Xiaochang, Xue, Zenglu, Wang, Yingqi, Zhang   +5 more
openaire   +2 more sources

Expression of CD20-specific chimeric antigen receptor (CD20-CAR) on Jurkat T cellsand evaluation its biological activity

Ministry of Science and Technology, Vietnam, 2022
CD20 is a potential target for immunotherapy treatments of haematological malignancies due to its specific expression and unique biological property. Over the years, many anti-CD20 monoclonal antibodies (mAbs) have been developed, such as Rituximab, Ibritumomab, Tositumomab, etc., and applied in B cells related to cancer treatments.
Nguyen Thanh Thao Vo, Dao Xuan Truc Chu, Dam Kim Tuyen Huynh, Thi Viet Anh Phung, Dang Quan Nguyen   +4 more
openaire   +1 more source

Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia

American Journal of Hematology, 1992
AbstractThe surface antigens expressed by the cells of chronic lymphocytic leukemia (CLL) are well known. Most CLL are monoclonal B‐cell lymphoproliferative disorders characterized by the coexpression of B‐cell antigens and CD5, an antigen present predominantly on T cells.
N M, Almasri, R E, Duque, J, Iturraspe, E, Everett, R C, Braylan   +4 more
openaire   +2 more sources

Analysis of cis-acting elements present in the CD20/B1 antigen promoter

The Journal of Immunology, 1991
Abstract A genomic clone spanning a large portion of the 5’ untranscribed region of the CD20 gene was isolated. Deletion analysis of subcloned fragments identified several regulatory elements. A major positive cis-acting element was localized between base pairs -290/-186.
P, Rieckmann, G L, Wilson, C, Thevenin, J X, Hong, J H, Kehrl   +4 more
openaire   +2 more sources

Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma

International Journal of Radiation Oncology*Biology*Physics, 2004
The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies. The properties of the target, CD20, and the mechanisms of action of both the monoclonal antibodies and the associated exponentially ...
M Carmen, Hernandez, Susan J, Knox
openaire   +2 more sources